Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study,
2022,
Fabian Trillsch ,
Sven Mahner ,
Beyhan Ataseven ,
Rebecca Asher ,
N. Aryal ,
Coraline Dubot ,
et al. ,
Tomasz Huzarski(*) ,
Antonio Casado ,
Giovanni Scambia ,
Michael Friedlander ,
et al. ,
Gynecologic Oncology, Vol. 165, Issue 1, 40--48, ISSN: 0090-8258, eISSN: 1095-6859,
bibliogr.
tab.
wykr.
summ.
Słowa kluczowe: Age dependency, Olaparib, Ovarian cancer, PARP inhibitors, Quality of life
Kod: CZR-N-WYKAZ
BibTeX
(pkt. 140)
DOI: 10.1016/j.ygyno.2022.01.024